TY - JOUR AU - Diaz, Caridad AU - Gonzalez-Olmedo, Carmen AU - Diaz-Beltran, Leticia AU - Camacho, Jose AU - Mena Garcia, Patricia AU - Martin-Blazquez, Ariadna AU - Fernandez-Navarro, Monica AU - Ortega-Granados, Ana Laura AU - Galvez-Montosa, Fernando AU - Marchal, Juan Antonio AU - Vicente, Francisca AU - Perez Del Palacio, Jose AU - Sanchez-Rovira, Pedro PY - 2022 DO - 10.1002/1878-0261.13216 UR - http://hdl.handle.net/10668/19508 T2 - Molecular oncology AB - Neoadjuvant chemotherapy (NACT) outcomes vary according to breast cancer (BC) subtype. Since pathologic complete response is one of the most important target endpoints of NACT, further investigation of NACT outcomes in BC is crucial. Thus, identifying... LA - en PB - John Wiley & Sons Ltd. KW - ASCA KW - LC-HRMS KW - breast cancer KW - neoadjuvant chemotherapy KW - personalized medicine KW - treatment response KW - Antineoplastic Combined Chemotherapy Protocols KW - Breast Neoplasms KW - Female KW - Humans KW - Metabolomics KW - Neoadjuvant Therapy TI - Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach. TY - research article VL - 16 ER -